根据提交至美国证券交易委员会（SEC）的文件显示，Mira Pharma旗下在研药物SKNY-1在临床前研究中展现出令人鼓舞的药代动力学特征。该化合物表现出良好的生物利用度，意味着口服后能够有效地被吸收进入体循环。
更为关键的是，研究数据揭示了SKNY-1在目标器官——大脑和肝脏中具有强劲的暴露水平。这种在关键组织中的高浓度分布，为其针对中枢神经系统或肝脏相关疾病的潜在疗效提供了重要的药理学基础。
基于其有利的药代动力学特性，特别是持久的体内作用时间，SKNY-1显示出有望实现每日一次给药的潜力。若在后续临床开发中得到证实，这种简便的给药方案将显著提高患者的用药依从性，成为该药物的一大竞争优势。
此次通过SEC文件披露的积极临床前数据，为Mira Pharma该研发项目的进展提供了官方背书，也为关注该公司未来发展的投资者提供了最新的科学依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.